Physician profile
Antonio Cabreira
NPI 1114125630
$1,060.70
in general payments reported to CMS, 2019-2025
24 companies · $14.68 in 2025
The $14.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $161 · 2021: $16.84 · 2022: $204 · 2023: $227 · 2024: $300 · 2025: $14.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $192.94 | 2020-2024 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $88.15 | 2019-2024 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $84.92 | 2023-2024 | Imfinzi, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $81.60 | 2019-2022 | |
| Seagen INC. | $72.76 | 2022-2023 | Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $63.52 | 2019-2024 | |
| Janssen Biotech, INC. | $62.16 | 2022-2024 | Rybrevant |
| Genzyme Corporation | $45.35 | 2022 | |
| Incyte Corporation | $44.55 | 2023-2025 | Jakafi |
| Eisai INC. | $33.26 | 2020 | |
| Amneal Pharmaceuticals LLC | $31.71 | 2023 | Avastin, Neupogen, Neulasta |
| Jazz Pharmaceuticals INC. | $24.81 | 2022 | |
| Pharmacosmos Therapeutics INC. | $23.38 | 2024 | Monoferric |
| Global Blood Therapeutics, INC. | $22.11 | 2022 | |
| Mirati Therapeutics, INC. | $22.08 | 2024 | Krazati |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.94 | 2019 | |
| Genentech USA, INC. | $20.22 | 2024 | Venclexta |
| Alnylam Pharmaceuticals INC. | $20.08 | 2023 | Givlaari |
| Abbvie INC. | $19.97 | 2024 | |
| Taiho Oncology, INC. | $19.96 | 2019 | |
| Agios Pharmaceuticals, INC. | $18.17 | 2023 | Pyrukynd |
| Morphosys, US INC. | $17.65 | 2022 | |
| Astellas Pharma US INC | $16.84 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Cabreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.